HUP0401863A2 - Autoimmun-betegségek szuppresszálására szolgáló aminosav-kopolimerek és alkalmazási eljárások - Google Patents

Autoimmun-betegségek szuppresszálására szolgáló aminosav-kopolimerek és alkalmazási eljárások

Info

Publication number
HUP0401863A2
HUP0401863A2 HU0401863A HUP0401863A HUP0401863A2 HU P0401863 A2 HUP0401863 A2 HU P0401863A2 HU 0401863 A HU0401863 A HU 0401863A HU P0401863 A HUP0401863 A HU P0401863A HU P0401863 A2 HUP0401863 A2 HU P0401863A2
Authority
HU
Hungary
Prior art keywords
copolymers
mbp
membered
hla
plp
Prior art date
Application number
HU0401863A
Other languages
English (en)
Inventor
Jack L. Strominger
Masha Fridkis-Hareli
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of HUP0401863A2 publication Critical patent/HUP0401863A2/hu
Publication of HUP0401863A3 publication Critical patent/HUP0401863A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)

Abstract

A találmány tárgyát 14, 35 és 50 tagú, 3 és 4 aminosavból álló randomaminosav-kopolimerek képezik. Az 50-tagú FEAK hatásos inhibitora azMBP 85-99 vagy proteolipid protein (PLP) 40-60-ra specifikus HLA-DR-2-korlátozott T-sejt-klónoknak. Ezek a kopolimerek hatásosanszuppresszálták az érzékeny SJL/J (H-2s) egértörzsekben a teljesgerincvelő homogenizátummal (WSCH) vagy a PLP 139-151enkefalitogenikus epitóppal indukált EAE-t. Az 50 tagú YFAK - amelyneka mólaránya körülbelül Y 0,8:F 0,2 - hatékonyabban gátolta abiotinilált MBP 85-99 epitóp kötődését a HLA-DR-2 molekulákhoz, mint ajelöletlen MBP 85-99 vagy a Copaxone<<. Az YFAK és FAK kopolimerekhatékonyan szuppresszálták az SJL/J (H-2s) egerekben a PLP 139-151enkefalitogenikus epitóppal indukált EAE-t. Az YFK, VYAK és atriptofánt tartalmazó VWAK kopolimerek hatásosak voltak az MBP 85-99peptiddel indukált EAE súlyosságának és a tünetek időtartamának azenyhítésére olyan humanizált egérmodellben, amely egyaránt expresszáltszklerózis multiplexszel (MS) kapcsolatos HLA-DR-2 géneket és egy MS-páciensből származó T-sejt-receptort. Ó
HU0401863A 2001-10-03 2002-10-03 Amino acid-copolymers for suppression of autoimmune diseases, and methods of use HUP0401863A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32670501P 2001-10-03 2001-10-03
PCT/US2002/031399 WO2003029276A2 (en) 2001-10-03 2002-10-03 Copolymers for suppression of autoimmune diseases, and methods of use

Publications (2)

Publication Number Publication Date
HUP0401863A2 true HUP0401863A2 (hu) 2004-12-28
HUP0401863A3 HUP0401863A3 (en) 2012-09-28

Family

ID=23273317

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401863A HUP0401863A3 (en) 2001-10-03 2002-10-03 Amino acid-copolymers for suppression of autoimmune diseases, and methods of use

Country Status (12)

Country Link
US (3) US7381790B2 (hu)
EP (2) EP2123669A1 (hu)
JP (3) JP5010798B2 (hu)
AU (1) AU2002362445B2 (hu)
CA (1) CA2462459C (hu)
DE (1) DE02800437T1 (hu)
HU (1) HUP0401863A3 (hu)
IL (2) IL161121A0 (hu)
NO (2) NO20041345L (hu)
NZ (1) NZ532199A (hu)
WO (1) WO2003029276A2 (hu)
ZA (1) ZA200402601B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005249A2 (en) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6930168B2 (en) * 2001-01-24 2005-08-16 The President And Fellows Of Harvard College Synthetic peptides for demyelinating conditions
CA2558655A1 (en) * 2004-03-01 2005-09-15 Kai W. Wucherpfennig Methods and compositions for treatment of autoimmune diseases
US20090275496A1 (en) * 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
WO2005120542A2 (en) * 2004-05-07 2005-12-22 Peptimmune, Inc. Methods of treating disease with random copolymers
WO2007120834A2 (en) 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
EP2586460A1 (en) 2007-10-16 2013-05-01 Peptimmune, Inc. Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes
WO2009075854A2 (en) * 2007-12-10 2009-06-18 Peptimmune Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
JP5916622B2 (ja) 2010-01-04 2016-05-11 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
ES2707500T3 (es) 2015-11-23 2019-04-03 Chemi Spa Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
WO2018006092A1 (en) * 2016-07-01 2018-01-04 Declion Holdings Llc Amino acid copolymer compositions and uses thereof
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
WO2022103673A2 (en) * 2020-11-10 2022-05-19 Fridkis Hareli Masha Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3052655A (en) * 1958-08-01 1962-09-04 Sidney W Fox Thermal polymerization of amino acid mixtures containing aspartic acid or a thermal precursor of aspartic acid
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4996292A (en) * 1989-06-30 1991-02-26 Fox Sidney W Self-sealing artificial skin comprising copoly-alpha-amino acid
AU8305491A (en) * 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
DE4423131A1 (de) 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
AU730477B2 (en) 1996-08-05 2001-03-08 President And Fellows Of Harvard College MHC binding peptide oligomers and methods of use
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
EP1066295A2 (en) 1998-03-23 2001-01-10 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
ZA200102269B (en) * 1998-09-25 2002-03-19 Yeda Res & Dev Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use.
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6930168B2 (en) 2001-01-24 2005-08-16 The President And Fellows Of Harvard College Synthetic peptides for demyelinating conditions
CN1516598A (zh) * 2001-06-22 2004-07-28 ��ͯ����ҽԺ 抗菌肽
US8017166B2 (en) 2004-11-01 2011-09-13 Steven Amory Twitty Method of producing stackable low-fat snack chips

Also Published As

Publication number Publication date
US20110286959A1 (en) 2011-11-24
EP1438061A2 (en) 2004-07-21
WO2003029276A2 (en) 2003-04-10
IL161121A (en) 2010-11-30
CA2462459C (en) 2007-12-18
JP2012162545A (ja) 2012-08-30
WO2003029276A3 (en) 2003-11-27
US7381790B2 (en) 2008-06-03
DE02800437T1 (de) 2004-11-11
JP5525749B2 (ja) 2014-06-18
ZA200402601B (en) 2005-07-27
EP1438061A4 (en) 2005-02-23
NZ532199A (en) 2008-02-29
IL161121A0 (en) 2004-08-31
HUP0401863A3 (en) 2012-09-28
US20080241099A1 (en) 2008-10-02
CA2462459A1 (en) 2003-04-10
EP1438061B1 (en) 2016-05-11
NO337092B1 (no) 2016-01-18
US9028835B2 (en) 2015-05-12
US20040038887A1 (en) 2004-02-26
NO20041759L (no) 2004-04-29
JP5010798B2 (ja) 2012-08-29
JP2009185057A (ja) 2009-08-20
EP2123669A1 (en) 2009-11-25
NO20041345L (no) 2004-03-31
AU2002362445B2 (en) 2006-09-21
US8017125B2 (en) 2011-09-13
JP2005511518A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
HUP0401863A2 (hu) Autoimmun-betegségek szuppresszálására szolgáló aminosav-kopolimerek és alkalmazási eljárások
Dagosto Implications of postcranial evidence for the origin of euprimates
JP2003513700A (ja) 歯間ブラシ
Sichting et al. Evolutionary anatomy of the plantar aponeurosis in primates, including humans
SG158733A1 (en) Cell adhesion inhibitors
EA200100103A1 (ru) Ингибиторы адгезии клеток
AU2003226014A8 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer&#39;s disease
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
KR20010006275A (ko) 면역계 활성을 조절하고 염증을 억제하기 위한 세포조절 친유성 펩티드
HUP0101317A2 (hu) Módosított VIII-as faktor
WO2004043352A3 (en) Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
Brandfonbrener Joint laxity and arm pain in a large clinical sample of musicians
US8230544B2 (en) Multipurpose cleaning brush
IL206650A0 (en) T cell receptor cdr3 peptide for treating an autoimmune disease
Alhendi et al. Systemic sclerosis: update for oral health care providers
AU761717B2 (en) Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
Muraille Generation of individual diversity: a too neglected fundamental property of adaptive immune system
IL111196A0 (en) Peptides and pharmaceutical compositions comprising them
WO2004043397A3 (en) Compositions and methods for the treatment of rheumatoid arthritis
US20180327636A1 (en) Disposable Handle Wrap Apparatus
Sofat et al. Hand osteoarthritis—Clinical presentation, phenotypes and management
Reinders et al. Survey on management of gout among Dutch rheumatologists
WO2004098489A3 (en) Compositions and methods for modulation of specific epitopes of hsp60
Chauhan et al. Continuing Education Activity
JP2008036329A (ja) 矯正装具

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished